Project Grant HT9425261E034
Award Date 4/1/26
Completion Date 3/31/29
Dollars Obligated $488K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tacoma, WA 98402, USA
Similar Awards
- Federal Project Grant Award Summary The Defense Health Agency awarded The Geneva Foundation a $747,394 Project Grant (CFDA 12.420: Military Medical Research and Development) effective April 1, 2026 through March 31, 2029 to conduct research on antagonism-enforced braking system CAR T-cells for the treatment of TP53-mutant breast cancer. This three-year initiative supports advanced biomedical research designed to develop innovative immunotherapies targeting a specific subset of breast cancers...
- Federal Project Grant Award Summary The Geneva Foundation received a $909,510 Project Grant awarded May 1, 2025, by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to support precision therapy research for the eradication of brain metastatic breast cancer. The three-year award, with an ultimate completion date of April 30, 2028, will be performed at the foundation's Tacoma, Washington facility. This research initiative aligns with the...
- Federal Project Grant Award Summary The Geneva Foundation received a $487,800 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective October 1, 2025 through September 30, 2027. The grant funds research to define the cellular origins and molecular vulnerabilities of Notch-driven lymphomas, advancing understanding of cancer biology and therapeutic targets. This research initiative aligns with the DHA's mission to...
- Federal Grant Award Summary The Geneva Foundation received a $1,009,750 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded August 1, 2025, for a three-year performance period ending July 31, 2028. The award supports genomic and functional characterization of chemoresistance in small cell lung cancer, a research initiative conducted at the foundation's facility in Tacoma, Washington. This project contributes to...
- Federal Project Grant Award Summary The Geneva Foundation received a $4.82 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded July 15, 2025, with a completion date of July 14, 2028. The award funds the development of a patient-matched segmental defect implant system with mechanobiologic activation and antimicrobial coating designed to treat severe fractures. This research initiative represents an...
- Federal Grant Award Summary The Defense Health Agency awarded The Geneva Foundation a $575,968 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 30, 2025, with a completion date of September 29, 2027. The award funds an efficacy and feasibility trial of a portable near-infrared hematoma imager designed to detect intracranial hemorrhage in acute care settings. This research initiative will be conducted at The Geneva Foundation's facility...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Geneva Foundation a $4.397 million project grant on November 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on extracorporeal immunomodulation to reduce inflammation following severe burns, inhalation injury, and septicemia. The three-year award, with an ultimate completion date of October 31, 2028, will be performed in Tacoma, Washington. This research...
- This Project Grant award for $366,000.00, awarded on Sep 30, 2024 by the Defense Health Agency, supports research conducted by The Geneva Foundation to identify functional structural variants that influence therapy outcomes for human castration-resistant prostate cancer. The award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a broad range of biomedical research initiatives to improve health outcomes for military service members,...
- The Geneva Foundation received a $453,029 Project Grant award from the Department of the Army Medical Command on February 1, 2021 to improve the therapeutic index of antibody drug conjugates targeting metastatic breast cancer. Funded through January 31, 2024 under the Military Medical Research and Development program (CFDA 12.420), this award will support the Foundation's work to transform healthcare and investigate medical solutions for the battlefield by developing more effective targeted...
- The Geneva Foundation was awarded a $362,100 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program to conduct research toward the dual targeting of HER2 and androgen receptor in patients with high-risk, hormone-naive prostate cancer with curative intent. The two-year grant project period runs from June 1, 2022 to May 31, 2024. Through this funding, The Geneva Foundation will perform applied medical research investigating...